IVD Infectious Disease Market Analysis by Product, by Test Location and Segment Forecasts to 2022

  • ID: 4414332
  • Report
  • 157 pages
  • Grand View Research
1 of 3

IVD Infectious Disease Market Analysis By Product (Instruments, Reagents, Software), By Technology, Application (MRSA, Streptococcus, Clostridium difficile, Vancomycin-resistant enterococci, Carbapenem-resistant bacteria testing, Respiratory virus, Candida, Tuberculosis and drug-resistant TB, Gastro-intestinal panel testing, Chlamydia, Gonorrhea, HPV, HIV, Hepatitis C, Hepatitis B), By Test Location And Segment Forecasts To 2022

The global IVD infectious disease market was valued at over USD 13 billion in 2014 and is expected to grow at a CAGR of 8.2% over the forecast period. Rising prevalence of infectious diseases, growing base of geriatric population, lower immunity levels, and rising awareness among people about communicable diseases are estimated to be high impact rendering drivers.

According to the WHO, over 36 million people around the globe were suffering from HIV infection in 2014. Demand is increasing for rapid diagnostic devices pertaining to qualitative analysis of such infections to take further preventive measures. For instance, OraQuick by OraSure is a PoCT, which has received the FDA approval in late 2012 for home use. It is reported to provide accurate results in less than 40 minutes.

Rising base of the geriatric population with decreasing immune levels is expected to provide a wide base for growth of this market. The Global Health and Aging report by the NIH states that geriatric population accounts for a major share of infectious disease in low-income countries. Older people are already suffering from various infections and are more vulnerable to additional infectious diseases.

 Application Insights

 In vitro diagnostic devices find applications in the testing of various infectious diseases. Some infections widely targeted by kit and instrument manufacturers include HIV, hospital-acquired infections such as MRSA, streptococcus, influenza, and hepatitis virus.

HIV is reported to be the most widely present infection in both developed as well as low-income countries. According to the WHO, around 2.0 million new cases of HIV were detected in 2014 worldwide. Of the affected population, over 17 million people are unaware of being affected and future dangers associated with HIV.

 HIV is also anticipated to grow at a very fast rate owing to increasing prevalence rate, the introduction of technologically advanced and self-testing kits, and high levels of unmet clinical needs in developing nations. Rising awareness levels and favorable government initiatives are further estimated to fuel market growth.

Product Insights

 The products are categorized into instruments, reagents, and software. Reagents constitute various molecular diagnostic kits and immunoassays used for in vitro diagnosis of infections. Reagents held the largest share in 2014 owing to the presence of a wide range of kits and extensive usage of immunoassays in communicable disease testing.

 Instruments are expected to witness lucrative growth over the forecast period. Instruments are specially used for detection and analysis of blood samples for infection causing micro-organisms. Some of the diagnostic instruments used in this market include cobas 4800 by Roche and BD Max from BD biosciences.

 Technology Insights

 The immunoassay was one of the dominating segments in 2014 with revenue generation of over USD 4.5 million. ELISA and chemiluminescence immunoassays are the widely used forms of immunochemistry over the forecast period. Cost-effective procedures, user-friendliness, and high acceptance rates in clinical laboratories are key factors attributing to the largest market share.

 Owing to associated benefits of molecular diagnostics such as improved accuracy, rapid results, and higher levels of specificity is estimated to grow at a significant growth rate over the decade.

 Kit development companies are collaborating with molecular instrument manufacturers for the development of assays for detection of infectious diseases. For instance, BD assay for MRSA detection is used in combination with Cepheid SmartCycler.

 Test Location Insights

 Central laboratories segment dominated the overall IVD infectious disease market in terms of revenue share over USD 7.3 million in 2014. High procedure volumes, the presence of skilled labor, and established infrastructure in handling infectious samples are factors responsible for the aforementioned market share.

 Increasing demand for rapid tests, growing initiatives for reducing healthcare spending by reducing hospital stays, and rising level of health conscious population are anticipated to increase market share of POC at lucrative growth rate. The CAGR of PoC testing for the infectious disease over the forecast period is expected to be around 10.3%.

 Regional Insights

 In 2014, North America was highest revenue generating region with a revenue share of over 35%. Major factors accounting for largest market share include a high level of R & D activities, the presence of sophisticated healthcare infrastructure coupled with high levels of disposable income, and technological advancements in the field of IVD infectious disease testing.

 Developing regions such as Asia Pacific and MEA are estimated to offer a huge platform for potential growth of this market. Sub-Saharan Africa is reported to be the most affected region for HIV infections and HBV prevalence is highest in East Asia and Africa. Economic growth over the decade coupled with changes in lifestyle habits in this region is anticipated to provide epidemiologic transition boosting the growth of IVD infectious disease market.

 Competitive Market Share Insights

 The industry is oligopolistic in nature by the dominance of major players such Roche Diagnostics, Abbott Laboratories, Alere, Gen-Probe, Inc. (a part of Hologic, Inc.), Becton Dickinson (BD) Company, Inc., Bio-Rad Laboratories, Siemens Healthcare, and bioMeriux SA.

 Key players in an attempt of gain stability are adopting strategies such as the development of specialized products. For example, Becton Dickinson and Company is developing BDViper system for diagnosis of CT/GC and HPV infection, which is expected to drive market growth.

 Analyst Perspective

 The scope of study encompasses key IVD instruments and kits used for infectious disease testing. The study includes insights from manufacturers, distributors, clinical laboratory experts, and new entrants in the industry.

Estimates and forecasts are based on a compilation of information acquired and analyzed using three models. Primary research was extensively conducted to validate results. Target respondents included end-users, manufacturers, researchers, and distributors.

 Consumer preference attributes

 The above illustration represents buyer perspectives and preferences. Most important factors affecting end-user preferences include accuracy and ease-of-use. Some other key factors include price and post-sale technical support.

Key questions answered by the report

  • What was the market size from 2014 to 2016?
  • What will be market growth till 2025 and what will be the resultant market forecast in the year?
  • How will the market drivers, restraints and future opportunities affect the market dynamics and a subsequent analysis of the associate trends?
  • What segment or region will drive or lead market growth and why?
  • A comprehensive mapping of the competitive landscape and the market participants' behavior.
  • What are the key sustainability strategies adopted by market players? An in-depth analysis of these strategies and their impact on competition and growth
READ MORE
Note: Product cover images may vary from those shown
2 of 3

Chapter 1 Methodology and Scope
1.1 Research Methodology
1.2 Research Scope & Assumptions
1.3 List of Data Sources

Chapter 2 Executive Summary

Chapter 3 In-Vitro Diagnostics (IVD) Infectious Disease - Industry Outlook
3.1 Market segmentation
3.2 Market Size and Growth Prospects
3.3 In-Vitro Diagnostics (IVD) Infectious Disease - Market dynamics
3.4 Impact Analysis
3.4.1 Market driver analysis
3.4.1.1 Increasing prevalence of target diseases
3.4.1.2 Rising demand for point of care treatment
3.4.1.3 Increasing demand for minimally invasive diagnostic procedures
3.4.1.4 Technology advancement
3.4.1.5 Growing healthcare expenditure
3.4.2 Market restraint analysis
3.4.2.1 Inefficiency to diagnose cancer at early stages
3.4.2.2 Presence of complicated regulatory framework
3.5 In-Vitro Diagnostics (IVD) infectious disease market industry trend analysis
3.6 In-Vitro Diagnostics (IVD) infectious disease market: PESTEL analysis
3.7 In-Vitro Diagnostics (IVD) infectious disease: Industry analysis Porter’s
3.8 In-Vitro Diagnostics (IVD) infectious disease company market share analysis, 2014

Chapter 4 In-Vitro Diagnostics (IVD) Infectious Disease Market Product Outlook
4.1 In-Vitro Diagnostics (IVD) Infectious Disease revenue share by product, 2012 & 2022
4.2 IVD infectious disease instruments market estimates and forecasts, 2012 - 2022 (USD Million)
4.3 IVD infectious disease reagents market estimates and forecasts, 2012 - 2022 (USD Million)
4.4 Software market estimates and forecasts, 2012 - 2022 (USD Million)

Chapter 5 In-Vitro Diagnostics (IVD) Infectious Disease Market Technology Outlook
5.1 In-Vitro Diagnostics (IVD) Infectious Disease revenue share by technology, 2012 & 2022
5.2 Immunochemistry market estimates and forecasts, 2012 - 2022 (USD Million)
5.3 Microbiology market estimates and forecasts, 2012 - 2022 (USD Million)
5.4 Molecular diagnostics market estimates and forecasts, 2012 - 2022 (USD Million)

Chapter 6 In-Vitro Diagnostics (IVD) Infectious Disease Market Application Outlook
6.1 In-Vitro Diagnostics (IVD) Infectious Disease revenue share by application, 2012 & 2022
6.2 MRSA market estimates and forecasts, 2012 - 2022 (USD Million)
6.3 Streptococcus market estimates and forecasts, 2012 - 2022 (USD Million)
6.4 Clostridium difficile market estimates and forecasts, 2012 - 2022 (USD Million)
6.5 Vancomycin-resistant enterococci market estimates and forecasts, 2012 - 2022 (USD Million)
6.6 Carbapenem-resistant bacteria testing market estimates and forecasts, 2012 - 2022 (USD Million)
6.7 Respiratory virus market estimates and forecasts, 2012 - 2022 (USD Million)
6.8 Candida market estimates and forecasts, 2012 - 2022 (USD Million)
6.9 Tuberculosis and drug-resistant TB market estimates and forecasts, 2012 - 2022 (USD Million)
6.10 Gastro-intestinal panel testing market estimates and forecasts, 2012 - 2022 (USD Million)
6.11 Chlamydia market estimates and forecasts, 2012 - 2022 (USD Million)
6.12 Gonorrhea market estimates and forecasts, 2012 - 2022 (USD Million)
6.13 HPV market estimates and forecasts, 2012 - 2022 (USD Million)
6.14 HIV market estimates and forecasts, 2012 - 2022 (USD Million)
6.15 Hepatitis C market estimates and forecasts, 2012 - 2022 (USD Million)
6.16 Hepatitis B market estimates and forecasts, 2012 - 2022 (USD Million)
6.17 Other infectious diseases market estimates and forecasts, 2012 - 2022 (USD Million)

Chapter 7 In-Vitro Diagnostics (IVD) Infectious Disease Market Test Location Outlook
7.1 In-Vitro Diagnostics (IVD) Infectious Disease revenue share by test location, 2012 & 2022
7.2 Point of Care market estimates and forecasts, 2012 - 2022 (USD Million)
7.3 Central Laboratories market estimates and forecasts, 2012 - 2022 (USD Million)
7.4 Others market estimates and forecasts, 2012 - 2022 (USD Million)

Chapter 8 In-Vitro Diagnostics (IVD) Infectious Disease Regional Outlook
8.1 North America
8.1.1 North America market estimates and forecasts, by product, 2012 - 2022 (USD Million)
8.1.1.1. U.S. market estimates and forecasts
8.1.1.2. Canada market estimates and forecasts
8.1.2 North America market estimates and forecasts, by technology, 2012 - 2022 (USD Million)
8.1.2.1. U.S. market estimates and forecasts
8.1.2.2. Canada market estimates and forecasts
8.1.3 North America market estimates and forecasts, by application, 2012 - 2022 (USD Million)
8.1.3.1. U.S. market estimates and forecasts
8.1.3.2. Canada market estimates and forecasts
8.1.4 North America market estimates and forecasts, by test location, 2012 - 2022 (USD Million)
8.1.4.1. U.S. market estimates and forecasts
8.1.4.2. Canada market estimates and forecasts
8.2 Europe
8.2.1 Europe market estimates and forecasts, by product, 2012 - 2022 (USD Million)
8.2.1.1. Germany market estimates and forecasts
8.2.1.2. UK market estimates and forecasts
8.2.2 Europe market estimates and forecasts, by technology, 2012 - 2022 (USD Million)
8.2.2.1. Germany market estimates and forecasts
8.2.2.2. UK market estimates and forecasts
8.2.3 Europe market estimates and forecasts, by application, 2012 - 2022 (USD Million)
8.2.3.1. Germany market estimates and forecasts
8.2.3.2. UK market estimates and forecasts
8.2.4 Europe market estimates and forecasts, by test location, 2012 - 2022 (USD Million)
8.2.4.1. Germany market estimates and forecasts
8.2.4.2.UK market estimates and forecasts
8.3 Asia Pacific
8.3.1 Asia Pacific market estimates and forecasts, by product, 2012 - 2022 (USD Million)
8.3.1.1. U.S. market estimates and forecasts
8.3.1.2. Canada market estimates and forecasts
8.3.2 Asia Pacific market estimates and forecasts, by technology, 2012 - 2022 (USD Million)
8.3.2.1. China market estimates and forecasts
8.3.2.2. Japan market estimates and forecasts
8.3.2.2.India market estimates and forecasts
8.3.3 Asia Pacific market estimates and forecasts, by application, 2012 - 2022 (USD Million)
8.3.3.1. China market estimates and forecasts
8.3.3.2. Japan market estimates and forecasts
8.3.3.2.India market estimates and forecasts
8.3.4 Asia Pacific market estimates and forecasts, by test location, 2012 - 2022 (USD Million)
8.3.4.1. China market estimates and forecasts
8.3.4.2. Japan market estimates and forecasts
8.3.4.2.India market estimates and forecasts
8.4 Latin America
8.4.1 Latin America market estimates and forecasts, by product, 2012 - 2022 (USD Million)
8.4.1.1. Brazil market estimates and forecasts
8.4.2 Latin America market estimates and forecasts, by technology, 2012 - 2022 (USD Million)
8.4.2.1. Brazil market estimates and forecasts
8.4.3 Latin America market estimates and forecasts, by application, 2012 - 2022 (USD Million)
8.4.3.1. Brazil market estimates and forecasts
8.4.4 Latin America market estimates and forecasts, by test location, 2012 - 2022 (USD Million)
8.4.4.1. Brazil market estimates and forecasts
8.5 MEA
8.5.1 MEA market estimates and forecasts, by product, 2012 - 2022 (USD Million)
8.5.1.1. South Africa market estimates and forecasts
8.5.2 MEA market estimates and forecasts, by technology, 2012 - 2022 (USD Million)
8.5.2.1. South Africa market estimates and forecasts
8.5.3 MEA market estimates and forecasts, by application, 2012 - 2022 (USD Million)
8.5.3.1. South Africa market estimates and forecasts
8.5.4 MEA market estimates and forecasts, by test location, 2012 - 2022 (USD Million)
8.5.4.1. South Africa market estimates and forecasts

List of Tables

Table 1 In-Vitro Diagnostics (IVD) Infectious Disease - Industry Summary & Critical Success Factors (CSFs)
Table 2 In-Vitro Diagnostics (IVD) Infectious Disease market, by product, 2012 - 2022 (USD million)
Table 3 In-Vitro Diagnostics (IVD) Infectious Disease market, by technology, 2012 - 2022 (USD million)
Table 4 In-Vitro Diagnostics (IVD) Infectious Disease market, by application, 2012 - 2022 (USD million)
Table 5 In-Vitro Diagnostics (IVD) Infectious Disease market, by test location, 2012 - 2022 (USD million)
Table 6 In-Vitro Diagnostics (IVD) Infectious Disease market, by region, 2012 - 2022 (USD million)
Table 7 In-Vitro Diagnostics (IVD) Infectious Disease - Key market driver analysis
Table 8 Point of care treatment (POCT)
Table 9 Healthcare expenditure levels, 2012
Table 10 In-Vitro Diagnostics (IVD) Infectious Disease- Key market restraint analysis
Table 11 IVD infectious disease Instruments revenue, 2012-2022, (USD Million)
Table 12 IVD infectious disease Reagents revenue, 2012-2022 (USD million)
Table 13 Software revenue, 2012-2022 (USD million)
Table 14 Immunochemistry revenue, 2012-2022, (USD Million)
Table 15 Microbiology revenue, 2012-2022 (USD million)
Table 16 Molecular diagnostics revenue, 2012-2022 (USD million)
Table 17 MRSA revenue, 2012-2022, (USD Million)
Table 18 Streptococcus revenue, 2012-2022 (USD million)
Table 19 Clostridium difficile revenue, 2012-2022 (USD million)
Table 20 Vancomycin-resistant enterococci revenue, 2012-2022 (USD million)
Table 21 Carbapenem-resistant bacteria testing revenue, 2012-2022 (USD million)
Table 22 Respiratory virus revenue, 2012-2022 (USD million)
Table 23 Candida revenue, 2012-2022 (USD million)
Table 24 Tuberculosis and drug-resistant TB revenue, 2012-2022 (USD million)
Table 25 Gastro-intestinal panel testing revenue, 2012-2022 (USD million)
Table 26 Chlamydia revenue, 2012-2022 (USD million)
Table 27 Gonorrhea revenue, 2012-2022 (USD million)
Table 28 HPV revenue, 2012-2022 (USD million)
Table 29 HIV revenue, 2012-2022 (USD million)
Table 30 Hepatitis C revenue, 2012-2022 (USD million)
Table 31 Hepatitis B revenue, 2012-2022 (USD million)
Table 32 Other Infectious Diseases revenue, 2012-2022 (USD million)
Table 33 Point of Care revenue, 2012-2022, (USD Million)
Table 34 Central Laboratories revenue, 2012-2022 (USD million)
Table 35 Others revenue, 2012-2022 (USD million)
Table 36 North America In-Vitro Diagnostics (IVD) Infectious Disease revenue, by product, 2012 - 2020 (USD million)
Table 37 North America In-Vitro Diagnostics (IVD) Infectious Disease revenue, by technology, 2012 - 2020 (USD million)
Table 38 North America In-Vitro Diagnostics (IVD) Infectious Disease revenue, by application, 2012 - 2020 (USD million)
Table 39 North America In-Vitro Diagnostics (IVD) Infectious Disease revenue, by test location, 2012 - 2020 (USD million)
Table 40 US In-Vitro Diagnostics (IVD) Infectious Disease revenue, by product, 2012 - 2020 (USD million)
Table 41 US In-Vitro Diagnostics (IVD) Infectious Disease revenue, by technology, 2012 - 2020 (USD million)
Table 42 US In-Vitro Diagnostics (IVD) Infectious Disease revenue, by application, 2012 - 2020 (USD million)
Table 43 US In-Vitro Diagnostics (IVD) Infectious Disease revenue, by test location, 2012 - 2020 (USD million)
Table 44 Canada In-Vitro Diagnostics (IVD) Infectious Disease revenue, by product, 2012 - 2020 (USD million)
Table 45 Canada In-Vitro Diagnostics (IVD) Infectious Disease revenue, by technology, 2012 - 2020 (USD million)
Table 46 Canada In-Vitro Diagnostics (IVD) Infectious Disease revenue, by application, 2012 - 2020 (USD million)
Table 47 Canada In-Vitro Diagnostics (IVD) Infectious Disease revenue, by test location, 2012 - 2020 (USD million)
Table 48 Europe In-Vitro Diagnostics (IVD) Infectious Disease revenue, by product, 2012 - 2020 (USD million)
Table 49 Europe In-Vitro Diagnostics (IVD) Infectious Disease revenue, by technology, 2012 - 2020 (USD million)
Table 50 Europe In-Vitro Diagnostics (IVD) Infectious Disease revenue, by application, 2012 - 2020 (USD million)
Table 51 Europe In-Vitro Diagnostics (IVD) Infectious Disease revenue, by test location, 2012 - 2020 (USD million)
Table 52 Germany In-Vitro Diagnostics (IVD) Infectious Disease revenue, by product, 2012 - 2020 (USD million)
Table 53 Germany In-Vitro Diagnostics (IVD) Infectious Disease revenue, by technology, 2012 - 2020 (USD million)
Table 54 Germany In-Vitro Diagnostics (IVD) Infectious Disease revenue, by application, 2012 - 2020 (USD million)
Table 55 Germany In-Vitro Diagnostics (IVD) Infectious Disease revenue, by test location, 2012 - 2020 (USD million)
Table 56 UK In-Vitro Diagnostics (IVD) Infectious Disease revenue, by product, 2012 - 2020 (USD million)
Table 57 UK In-Vitro Diagnostics (IVD) Infectious Disease revenue, by technology, 2012 - 2020 (USD million)
Table 58 UK In-Vitro Diagnostics (IVD) Infectious Disease revenue, by application, 2012 - 2020 (USD million)
Table 59 UK In-Vitro Diagnostics (IVD) Infectious Disease revenue, by test location, 2012 - 2020 (USD million)
Table 60 Asia Pacific In-Vitro Diagnostics (IVD) Infectious Disease revenue, by product, 2012 - 2020 (USD million)
Table 61 Asia Pacific In-Vitro Diagnostics (IVD) Infectious Disease revenue, by technology, 2012 - 2020 (USD million)
Table 62 Asia Pacific In-Vitro Diagnostics (IVD) Infectious Disease revenue, by application, 2012 - 2020 (USD million)
Table 63 Asia Pacific In-Vitro Diagnostics (IVD) Infectious Disease revenue, by test location, 2012 - 2020 (USD million)
Table 64 Japan In-Vitro Diagnostics (IVD) Infectious Disease revenue, by product, 2012 - 2020 (USD million)
Table 65 Japan In-Vitro Diagnostics (IVD) Infectious Disease revenue, by technology, 2012 - 2020 (USD million)
Table 66 Japan In-Vitro Diagnostics (IVD) Infectious Disease revenue, by application, 2012 - 2020 (USD million)
Table 67 Japan In-Vitro Diagnostics (IVD) Infectious Disease revenue, by test location, 2012 - 2020 (USD million)
Table 68 China In-Vitro Diagnostics (IVD) Infectious Disease revenue, by product, 2012 - 2020 (USD million)
Table 69 China In-Vitro Diagnostics (IVD) Infectious Disease revenue, by technology, 2012 - 2020 (USD million)
Table 70 China In-Vitro Diagnostics (IVD) Infectious Disease revenue, by application, 2012 - 2020 (USD million)
Table 71 China In-Vitro Diagnostics (IVD) Infectious Disease revenue, by test location, 2012 - 2020 (USD million)
Table 72 Latin America In-Vitro Diagnostics (IVD) Infectious Disease revenue, by product, 2012 - 2020 (USD million)
Table 73 Latin America In-Vitro Diagnostics (IVD) Infectious Disease revenue, by technology, 2012 - 2020 (USD million)
Table 74 Latin America In-Vitro Diagnostics (IVD) Infectious Disease revenue, by application, 2012 - 2020 (USD million)
Table 75 Latin America In-Vitro Diagnostics (IVD) Infectious Disease revenue, by test location, 2012 - 2020 (USD million)
Table 76 Brazil In-Vitro Diagnostics (IVD) Infectious Disease revenue, by product, 2012 - 2020 (USD million)
Table 77 Brazil In-Vitro Diagnostics (IVD) Infectious Disease revenue, by technology, 2012 - 2020 (USD million)
Table 78 Brazil In-Vitro Diagnostics (IVD) Infectious Disease revenue, by application, 2012 - 2020 (USD million)
Table 79 Brazil In-Vitro Diagnostics (IVD) Infectious Disease revenue, by test location, 2012 - 2020 (USD million)
Table 80 MEA In-Vitro Diagnostics (IVD) Infectious Disease revenue, by product, 2012 - 2020 (USD million)
Table 81 MEA In-Vitro Diagnostics (IVD) Infectious Disease revenue, by technology, 2012 - 2020 (USD million)
Table 82 MEA In-Vitro Diagnostics (IVD) Infectious Disease revenue, by application, 2012 - 2020 (USD million)
Table 83 MEA In-Vitro Diagnostics (IVD) Infectious Disease revenue, by test location, 2012 - 2020 (USD million)
Table 84 South Africa In-Vitro Diagnostics (IVD) Infectious Disease revenue, by product, 2012 - 2020 (USD million)
Table 85 South Africa In-Vitro Diagnostics (IVD) Infectious Disease revenue, by technology, 2012 - 2020 (USD million)
Table 86 South Africa In-Vitro Diagnostics (IVD) Infectious Disease revenue, by application, 2012 - 2020 (USD million)
Table 87 South Africa In-Vitro Diagnostics (IVD) Infectious Disease revenue, by test location, 2012 - 2020 (USD million)

List of Figures

FIG. 1 In-Vitro Diagnostics (IVD) Infectious Disease: Market Segmentation
FIG. 2 In-Vitro Diagnostics (IVD) Infectious Disease Market Revenue, 2012 – 2020 (USD million)
FIG. 3 In-Vitro Diagnostics (IVD) Infectious Disease Market Dynamics
FIG. 4 Key Opportunities Prioritized
FIG. 5 In-Vitro Diagnostics (IVD) Infectious Disease – Porter’s Analysis
FIG. 6 Asia Pacific PoC Diagnostics – PESTEL Analysis
FIG. 7 In-Vitro Diagnostics (IVD) Infectious Disease revenue share by product, 2012 & 2022
FIG. 8 In-Vitro Diagnostics (IVD) Infectious Disease revenue share by technology, 2012 & 2022
FIG. 9 In-Vitro Diagnostics (IVD) Infectious Disease revenue share by application, 2012 & 2022
FIG. 10 In-Vitro Diagnostics (IVD) Infectious Disease revenue share by test location, 2012 & 2022
FIG. 11 In-Vitro Diagnostics (IVD) Infectious Disease revenue share by region, 2014 & 2022
FIG. 12 North America In-Vitro Diagnostics (IVD) Infectious Disease revenue, 2012 - 2022 (USD million)
FIG. 13 US In-Vitro Diagnostics (IVD) Infectious Disease revenue, 2012 - 2022 (USD million)
FIG. 14 Canada In-Vitro Diagnostics (IVD) Infectious Disease revenue, 2012 - 2022 (USD million)
FIG. 15 Europe In-Vitro Diagnostics (IVD) Infectious Disease revenue, 2012 - 2022 (USD million)
FIG. 16 Germany In-Vitro Diagnostics (IVD) Infectious Disease revenue, 2012 - 2022 (USD million)
FIG. 17 UK In-Vitro Diagnostics (IVD) Infectious Disease revenue, 2012 - 2022 (USD million)
FIG. 18 Asia Pacific In-Vitro Diagnostics (IVD) Infectious Disease revenue, 2012 - 2022 (USD million)
FIG. 19 Japan In-Vitro Diagnostics (IVD) Infectious Disease revenue, 2012 - 2022 (USD million)
FIG. 20 China In-Vitro Diagnostics (IVD) Infectious Disease revenue, 2012 - 2022 (USD million)
FIG. 21 Latin America In-Vitro Diagnostics (IVD) Infectious Disease revenue, 2012 - 2022 (USD million)
FIG. 22 Brazil In-Vitro Diagnostics (IVD) Infectious Disease revenue, 2012 - 2022 (USD million)
FIG. 23 MEA In-Vitro Diagnostics (IVD) Infectious Disease revenue, 2012 - 2022 (USD million)
FIG. 24 South Africa In-Vitro Diagnostics (IVD) Infectious Disease revenue, 2012 - 2022 (USD million)

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll